Lv1
40 积分 2024-12-24 加入
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
11天前
已完结
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
11天前
已关闭
Epidemiology and risk factors of invasive pulmonary fungal disease in patients with lung cancer
14天前
已关闭
Outcomes Following Immunotherapy Re-Challenge After Immune-Related Adverse Event: Systematic Review and Meta-Analysis
2个月前
已关闭
Outcomes Following Immunotherapy Re-Challenge After Immune-Related Adverse Event: Systematic Review and Meta-Analysis
2个月前
已关闭
Efficacy and safety of immune checkpoint inhibitor rechallenge following immune-related adverse events: a review
2个月前
已完结
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
2个月前
已完结
Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib
3个月前
已完结
Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study
3个月前
已完结
Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022
5个月前
已完结
皖公网安备34019202002308
